

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
May 15th, 2025

Company: Chordia Therapeutics Inc.
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: Head of Corporate Management Yoshihiko Satoh

Notice Concerning Change of Major Shareholder

Kanagawa Japan

May 15th, 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; Chief Executive Officer: Hiroshi Miyake) (“Chordia”) today announces that there has been a change of the major shareholder of the Company on May 14th, 2025, as described below.

1. Background for the change

A change in a major shareholder was recognized since the following shareholder informed that the percentage of voting rights has decreased as a result of the sales of common stock of the Company.

(1)	Name	Innovation Kyoto 2016 Investment Limited Liability Partnership
(2)	Location	36-1 Yoshida Honmachi, Sakyo-ku, Kyoto, Japan
(3)	General Partner	Kyoto University Innovation Capital Co., Ltd. President and CEO Ko Kusumi
(4)	Description of business	Venture Capital

2. Number of voting rights (number of shares) held by the shareholder and its ratio to the voting rights held by all shareholders before and after the change.

	Number of voting rights (Number of shares held)	Ratio of voting rights held	Ranking among major shareholders
Before the change (As of Feb 28 th , 2025)	70,000 units (7,000,000 shares)	10.14%	3rd
After the change	68,950 units (6,895,000 shares)	9.99%	3rd

*1 The above information is based on the notice received from Innovation Kyoto 2016 Investment Limited Liability Partnership, and the number of shares and voting rights actually held by the company have not been confirmed.

*2 The “Number of voting rights (number of shares held)” before the change is based on the shareholder register as of February 28, 2025.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



*3 The “Ratio of voting rights held” before the change is calculated based on the total number of voting rights of 689,786 as of February 28, 2025, and rounded down to the second decimal place.

*4 The “Ratio of voting rights held” after the change is calculated based on the total number of voting rights (689,786) used to calculate the ratio of the number of voting rights held to the total number of voting rights before the change and rounded down to the second decimal place.

3. Future outlook

This change will have no impact on the Company's management and business performance.